Jasna Canadi

Pharmacokinetics of serelaxin in patients with hepatic impairment: a single‐dose, open‐label, parallel group study

Zhanna Kobalava, S. V. Villevalde, Yu. V. Kotovskaya et al. · British Journal of Clinical Pharmacology · 2014 · 35 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Safety and tolerability of serelaxin, a recombinant human relaxin‐2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations

Marion Dahlke, Dik Ng, Masayuki Yamaguchi et al. · The Journal of Clinical Pharmacology · 2014 · 32 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Pharmacokinetics of serelaxin in patients with severe renal impairment or end‐stage renal disease requiring hemodialysis: A single‐dose, open‐label, parallel‐group study

Marion Dahlke, Atef Halabi, Jasna Canadi et al. · The Journal of Clinical Pharmacology · 2015 · 27 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs

Scott P. Henry, Cecilia Arfvidsson, Josh Arrington et al. · Nucleic Acid Therapeutics · 2022 · 19 citations

Pharmacy, Immunology, Pharmacology +17

Reduction of matrix interferences by the combination of chaotropic salt and DMSO in a broadly applicable target-based ELISA for pharmacokinetic studies of therapeutic monoclonal antibodies

Julie Doucet, Jasna Canadi, Christoph Kalis et al. · Journal of Pharmaceutical and Biomedical Analysis · 2009 · 10 citations

Pharmacy, Pharmacokinetics, Pharmacology +13